Stay updated on Sepofarsen Repeat-dose in LCA10 Clinical Trial
Sign up to get notified when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.

Latest updates to the Sepofarsen Repeat-dose in LCA10 Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added; the notice about lapse in government funding was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the site revision to v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary display and updated UI/metadata to show 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0' (replacing lowercase labels and the older revision tag). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4 with no substantive content changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedNo additions or deletions affecting the study details page were detected; the content appears unchanged.SummaryDifference0.1%

- Check57 days agoChange DetectedThe new screenshot appears to reflect minor formatting updates to the Study Details page without altering core trial information such as the NCT number, conditions, locations, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Sepofarsen Repeat-dose in LCA10 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.